Institution
Catholic University of the Sacred Heart
Education•Milan, Lombardia, Italy•
About: Catholic University of the Sacred Heart is a education organization based out in Milan, Lombardia, Italy. It is known for research contribution in the topics: Population & Health care. The organization has 13592 authors who have published 31048 publications receiving 853961 citations.
Topics: Population, Health care, Cancer, Myocardial infarction, Transplantation
Papers published on a yearly basis
Papers
More filters
••
TL;DR: These adolescents use the Internet for many hours per week; most utilize dysfunctional coping strategies and show worse interpersonal relations than peers who do not show signs of PIU.
Abstract: International literature has identified a stable correlation between problems in the sphere of adolescents' personal relationships and potential Internet dependence. The objective of this research is to verify in an Italian context the relationship among problematic Internet use (PIU), the quality of interpersonal relationships, and the cognitive strategies habitually used by adolescents to face daily problems. The participants in the research were 98 adolescents ages 14 to 19 (M = 16.28 years). The following instruments were administered to the participants: the Internet Addiction Test (IAT), the Test of Interpersonal Relationships (TRI); and the Children's Coping Strategies Checklist (CCSC). Parents of the participants were administered the Child Behavior Checklist (CBCL). Of the participants, 36.7% showed signs of PIU. These adolescents use the Internet for many hours per week; most utilize dysfunctional coping strategies and show worse interpersonal relations than peers who do not show signs ...
285 citations
••
University of Texas MD Anderson Cancer Center1, City of Hope National Medical Center2, University of Pennsylvania3, University of Kansas4, University of Nottingham5, German Cancer Research Center6, Paris Diderot University7, Vancouver General Hospital8, University of California, Davis9, University of Hong Kong10, Carlos III Health Institute11, University of Mainz12, Catholic University of the Sacred Heart13, Daiichi Sankyo14, Johns Hopkins University15
TL;DR: This trial aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival versus salvage chemotherapy in the intention-to-treat population of patients with relapsed or refractory acute myeloid leukaemia.
Abstract: Summary Background Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease. We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival versus salvage chemotherapy. Methods QuANTUM-R is a randomised, controlled, phase 3 trial done at 152 hospitals and cancer centres in 19 countries. Eligible patients aged 18 years or older with ECOG performance status 0–2 with relapsed or refractory (duration of first composite complete remission ≤6 months) FLT3-ITD acute myeloid leukaemia after standard therapy with or without allogeneic haemopoietic stem-cell transplantation were randomly assigned (2:1; permuted block size of 6; stratified by response to previous therapy and choice of chemotherapy via a phone-based and web-based interactive response system) to quizartinib (60 mg [30 mg lead-in] orally once daily) or investigator's choice of preselected chemotherapy: subcutaneous low-dose cytarabine (subcutaneous injection of cytarabine 20 mg twice daily on days 1–10 of 28-day cycles); intravenous infusions of mitoxantrone (8 mg/m2 per day), etoposide (100 mg/m2 per day), and cytarabine (1000 mg/m2 per day on days 1–5 of up to two 28-day cycles); or intravenous granulocyte colony-stimulating factor (300 μg/m2 per day or 5 μg/kg per day subcutaneously on days 1–5), fludarabine (intravenous infusion 30 mg/m2 per day on days 2–6), cytarabine (intravenous infusion 2000 mg/m2 per day on days 2–6), and idarubicin (intravenous infusion 10 mg/m2 per day on days 2–4 in up to two 28-day cycles). Patients proceeding to haemopoietic stem-cell transplantation after quizartinib could resume quizartinib after haemopoietic stem-cell transplantation. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02039726, and follow-up is ongoing. Findings Between May 7, 2014, and Sept 13, 2017, 367 patients were enrolled, of whom 245 were randomly allocated to quizartinib and 122 to chemotherapy. Four patients in the quizartinib group and 28 in the chemotherapy group were not treated. Median follow-up was 23·5 months (IQR 15·4–32·3). Overall survival was longer for quizartinib than for chemotherapy (hazard ratio 0·76 [95% CI 0·58–0·98; p=0·02]). Median overall survival was 6·2 months (5·3–7·2) in the quizartinib group and 4·7 months (4·0–5·5) in the chemotherapy group. The most common non-haematological grade 3–5 treatment-emergent adverse events (within ≤30 days of last dose or >30 days if suspected to be a treatment-related event) for quizartinib (241 patients) and chemotherapy (94 patients) were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [19%] for chemotherapy), pneumonia (29 [12%] vs eight [9%]), and hypokalaemia (28 [12%] vs eight [9%]). The most frequent treatment-related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic shock (11 [5%]), QT prolongation (five [2%]), and nausea (five [2%]) in the quizartinib group, and febrile neutropenia (five [5%]), sepsis or septic shock (four [4%]), pneumonia (two [2%]), and pyrexia (two [2%]) in the chemotherapy group. Grade 3 QT prolongation in the quizartinib group was uncommon (eight [3%] by central reading, ten [4%] by investigator report); no grade 4 events occurred. There were 80 (33%) treatment-emergent deaths in the quizartinib group (31 [13%] of which were due to adverse events) and 16 (17%) in the chemotherapy group (nine [10%] of which were due to adverse events). Interpretation Treatment with quizartinib had a survival benefit versus salvage chemotherapy and had a manageable safety profile in patients with rapidly proliferative disease and very poor prognosis. Quizartinib could be considered a new standard of care. Given that there are only a few available treatment options, this study highlights the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor. Funding Daiichi Sankyo.
285 citations
••
Otto-von-Guericke University Magdeburg1, University of Sfax2, University of Münster3, German Center for Neurodegenerative Diseases4, University of Gafsa5, Rio de Janeiro State University6, University of Twente7, Estácio S.A.8, Canadian University of Dubai9, Imam Khomeini International University10, University of Paris11, York University12, University of Genoa13, Paris West University Nanterre La Défense14, University of Thessaly15, Loughborough University16, Stanford University17, University of Toulouse18, Assiut University19, Karlsruhe Institute of Technology20, Georgia Southern University21, Government of Extremadura22, University Medical Center Groningen23, University of Ulm24, Yarmouk University25, University of Jordan26, University of Porto27, ISCTE – University Institute of Lisbon28, Catholic University of the Sacred Heart29, Józef Piłsudski University of Physical Education in Warsaw30, University of Sousse31, University of Arkansas32, Manouba University33
TL;DR: The preliminary findings elucidate the risk of psychosocial strain during the early COVID-19 home confinement period in 2020 and suggest implementation of national strategies focused on promoting social inclusion through a technology-based solution is strongly suggested.
Abstract: Public health recommendations and governmental measures during the new coronavirus disease (COVID-19) pandemic have enforced numerous restrictions on daily living including social distancing, isolation, and home confinement. While these measures are imperative to mitigate spreading of COVID-19, the impact of these restrictions on psychosocial health is undefined. Therefore, an international online survey was launched in April 2020 to elucidate the behavioral and lifestyle consequences of COVID-19 restrictions. This report presents the preliminary results from more than one thousand responders on social participation and life satisfaction. Methods: Thirty-five research organizations from Europe, North-Africa, Western Asia, and the Americas promoted the survey through their networks to the general society, in 7 languages (English, German, French, Arabic, Spanish, Portuguese, and Slovenian). Questions were presented in a differential format with questions related to responses “before” and “during” confinement conditions. Results: 1047 participations (54% women) from Asia (36%), Africa (40%), Europe (21%), and others (3%) were included in the analysis. Findings revealed psychosocial strain during the enforced COVID-19 home confinement. Large decreases (p < 0.001) in the amount of social activity through family (−58%), friends/neighbors (−44.9%), or entertainment (−46.7%) were triggered by the enforced confinement. These negative effects on social participation were also associated with lower life satisfaction (−30.5%) during the confinement period. Conversely, the social contact score through digital technologies significantly increased (p < 0.001) during the confinement period with more individuals (+24.8%) being socially connected through digital technology. Conclusion: These preliminary findings elucidate the risk of psychosocial strain during the early COVID-19 home confinement period in 2020. Therefore, in order to mitigate the negative psychosocial effects of home confinement, implementation of national strategies focused on promoting social inclusion through a technology-based solution is strongly suggested.
284 citations
••
TL;DR: The evidence-based Italian Association for the Study of Liver guidelines for the appropriate diagnosis and management of patients with nonalcoholic fatty liver disease in clinical practice and its related research agenda are reported.
284 citations
••
TL;DR: It is shown that texture discrimination can be artificially provided in human subjects by implementing a neuromorphic real-time mechano-neuro-transduction (MNT) process, which emulates to some extent the firing dynamics of SA1 cutaneous afferents.
Abstract: Restoration of touch after hand amputation is a desirable feature of ideal prostheses. Here, we show that texture discrimination can be artificially provided in human subjects by implementing a neuromorphic real-time mechano-neuro-transduction (MNT), which emulates to some extent the firing dynamics of SA1 cutaneous afferents. The MNT process was used to modulate the temporal pattern of electrical spikes delivered to the human median nerve via percutaneous microstimulation in four intact subjects and via implanted intrafascicular stimulation in one transradial amputee. Both approaches allowed the subjects to reliably discriminate spatial coarseness of surfaces as confirmed also by a hybrid neural model of the median nerve. Moreover, MNT-evoked EEG activity showed physiologically plausible responses that were superimposable in time and topography to the ones elicited by a natural mechanical tactile stimulation. These findings can open up novel opportunities for sensory restoration in the next generation of neuro-prosthetic hands.
284 citations
Authors
Showing all 13795 results
Name | H-index | Papers | Citations |
---|---|---|---|
Peter J. Barnes | 194 | 1530 | 166618 |
Cornelia M. van Duijn | 183 | 1030 | 146009 |
Dennis R. Burton | 164 | 683 | 90959 |
Paolo Boffetta | 148 | 1455 | 93876 |
Massimo Antonelli | 130 | 1272 | 79319 |
David B. Audretsch | 126 | 671 | 72456 |
Piero Anversa | 115 | 412 | 60220 |
Marco Pahor | 112 | 476 | 46549 |
David L. Paterson | 111 | 739 | 68485 |
Alfonso Caramazza | 108 | 451 | 39280 |
Anthony A. Amato | 105 | 911 | 57881 |
Stefano Pileri | 100 | 635 | 43369 |
Giovanni Gasbarrini | 98 | 894 | 36395 |
Giampaolo Merlini | 96 | 684 | 40324 |
Silvio Donato | 96 | 860 | 41166 |